Racial and ethnic differences in the severity, prognosis, and mortality of multiple sclerosis (MS) have been the focus of ...

The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...

Baseline tumor-infiltrating lymphocytes and positive nodes can help identify women with TMBC at high risk for relapse despite ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Roche (RHHBF) unit Genentech partners Orionis Biosciences to develop and commercialize cancer drugs in a deal that exceed $2B ...

Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration ...

The schema newly classified 15.4% of persons without airflow obstruction as having COPD by minor diagnostic category, Surya P ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

Columvi combo for relapsed diffuse large B-cell lymphoma faces approval hurdle. Discover implications for U.S. Read more here ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...